Brief: X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
06/02/2025 12:56
Feb 6 (Reuters) - X4 Pharmaceuticals Inc XFOR.O :
* X4 PHARMACEUTICALS ANNOUNCES STRATEGIC RESTRUCTURING TO
DRIVE
VALUE AND MAXIMIZE OPPORTUNITY FOR MAVORIXAFOR IN CHRONIC
NEUTROPENIA
* X4 PHARMACEUTICALS INC - TO REDUCE HEADCOUNT BY 43 PEOPLE,
CLOSE
VIENNA FACILITY
* X4 PHARMACEUTICALS INC - RESTRUCTURING EXPECTED TO EXTEND
CASH
RUNWAY INTO H1 2026
Source text: ID:nGNX9d0Rj0
Further company coverage: XFOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule